AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03391115 — intervention group
Intervention type: BEHAVIORAL
Intervention: Storytelling Intervention for Nurse Participants
Description: Once the patient's story is uploaded to the EHR, automatic alerts will be sent to the participant's EHR-assigned nurses. For usability testing, nurse participants will 1) provide content expertise of the workflow processes, and 2) put the storytelling intervention through in-house usability testing to check the strength of EHR features and user-friendliness. Data will be collected with exit interviews and completion of a questionnaire: the System Usability Scale which asks them to rank their satisfaction with specific elements such as: how the story is labeled and presented in the EHR, any technical navigation EHR difficulties, and use of the material.
Study NCT04022941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Benzoate
Description: Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5 days.
Study NCT04022941 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Powdered table sugar as palcebo
Description: Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
Study NCT04600739 — intervention group
Intervention type: PROCEDURE
Intervention: TAVI
Description: Replacement of the aortic valve using a biological prosthesis that is inserted via a catheter.
Study NCT01711567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir
Description: tenofovir 300 mg qd
Study NCT01711567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir
Description: entecavir 0.5 mg qd
Study NCT02627274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6874281
Description: RO6874281 will be administered as per the schedule specified under arm description.
Study NCT02627274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per the schedule specified under arm description.
Study NCT02627274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered as per the schedule specified under arm description.
Study NCT02310841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANGELAA
Description: Different control strategies with transfemoral prosthesis prototype ANGELAA, developed at the Sensory-Motor Systems Lab, ETH Zurich, not commercially available, only 1 device exists
Study NCT01602380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: faslodex 500mg
Description: 2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
Study NCT01602380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arimidex 1mg
Description: oral tablet 1 daily
Study NCT01602380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: faslodex dummy
Description: 2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
Study NCT01602380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arimidex dummy
Description: oral tablet 1 daily
Study NCT02951819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m\^2 ) on Days 1, 8, 15, and 22 for every 28 days.
Study NCT02951819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.
Study NCT02951819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).
Study NCT03278041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submental flap for palatal reconstruction
Description: Under General Anesthesia the tumor in the maxilla will be resected (partial maxillectomy) with a safety margin, then the defect will be reconstructed immediately by :~Submental artery flap : from submental area with 1 cm distance from inferior mandibular border in paddle shape.~* 1st step will be identify the facial artery and vein,~* 2nd step dissection and extend toward midline in subplatsmal plane. The flap contains submental artery and vein.~* 3rd step creating submucous tunnel between vestibular border of post maxillectomy defect and to extraoral incision .~The flap will be through the oral cavity and will be anchored to the intact remaining hard plate with bone sutures by 2-0 vicryl® suture.
Study NCT03278041 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary obturator
Description: immediate surgical obturator
Study NCT03671018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (IV)
Description: Participants will receive intravenous (IV) mosunetuzumab.
Study NCT03671018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (SC)
Description: Participants will receive subcutaneous (SC) mosunetuzumab.
Study NCT03671018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Participants will receive IV polatuzumab vedotin.
Study NCT03671018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed.
Study NCT03671018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive IV rituximab.
Study NCT01443312 — intervention group
Intervention type: GENETIC
Intervention: Laboratory analysis.
Description: The blood transfusions given to the patients are in accord to physician decision and not related to the study
Study NCT03173378 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will have to complete questionnaires to compare the distribution of occupational situations in narcoleptic patients and matched non-narcoleptic subjects (controls)
Study NCT01930708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Administered as per the approved dosage in all countries where DMF has received marketing authorization.
Study NCT03448653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colonoscopy with NBI
Description: Colonoscopy with NBI
Study NCT03350620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVK-002 Concentration 1
Description: Study medication will be administered, once daily (QD)
Study NCT03350620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVK-002 Concentration 2
Description: Study medication will be administered, once daily (QD)
Study NCT03350620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle (placebo) will be administered, once daily (QD)
Study NCT03773965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.
Study NCT03051854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with children - for teachers
Description: Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
Study NCT03875235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
Study NCT03875235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
Study NCT01821170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological tests
Description: neuropsychological tests will assess attentional and executive performance
Study NCT02897973 — intervention group
Intervention type: OTHER
Intervention: Activity of daily living
Description: walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending
Study NCT05966909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler Ultrasound
Description: Ultrasound diagnosi of asymptomatic and symptomatic upper extremities vein thrombosis
Study NCT01467362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0034CR01B
Description: Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
Study NCT01467362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
Study NCT01467362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desonide 0.1% cream
Description: cream, once a day (in the evening) during flares
Study NCT01467362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: desonide 0.1% cream
Description: cream, once a day (in the evening) during flares
Study NCT01467362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foaming gel
Description: for the washing and cleaning
Study NCT01467362 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Foaming gel
Description: for the washing and cleaning
Study NCT03316976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole delayed-release capsule.
Study NCT02172469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation powder capsule
Study NCT02172469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Metered Dose Inhaler
Study NCT02172469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium Bromide Metered Dose Inhaler
Study NCT02172469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo inhalation powder capsule
Study NCT00683592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilazodone
Description: titration to 40 mg tablets qd (once a day) for 8 weeks
Study NCT02661815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Please see arm/group description.
Study NCT02661815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ricolinostat
Description: Please see arm/group description.
Study NCT02661815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Please see arm/group description.
Study NCT02557919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Training
Description: 1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.
Study NCT02557919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Best Practice
Description: .5 day training on tobacco control and emerging products.
Study NCT02103179 — intervention group
Intervention type: PROCEDURE
Intervention: surgical treatment
Description: all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
Study NCT01443026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene 30mg
Description: Lycopene 30 mg.
Study NCT01443026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01390103 — intervention group
Intervention type: OTHER
Intervention: Assessment following hip injection
Description: Assessment to evaluate the effect of the hip injection on biomechanics.
Study NCT04386057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle
Study NCT03541603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
Study NCT03541603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: A sterile 2.5mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
Study NCT04386057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: LY3214996-daily oral dosage per protocol per 28 day cycle
Study NCT02637622 — intervention group
Intervention type: OTHER
Intervention: Best-Worst Scaling (Case 2)
Description: Respondents receive questions asking them to choose the best and worst features of a hypothetical medication.
Study NCT02637622 — intervention group
Intervention type: OTHER
Intervention: Discrete Choice Experiment
Description: Respondents receive questions asking them to choose the medication they prefer between a pair of hypothetical medications.
Study NCT04411069 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Droperidol
Description: Pacients who had nausea and vomiting induced by chemotherapy will receive three anti emetic drugs: 4mg dexametasone, 4 mg ondansetron and 0,625 mg droperidol
Study NCT02005926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wire-localized abnormal node
Description: Before the sentinel lymph node biopsy (SLNB) operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance to localize the abnormal node. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
Study NCT02393625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib (LDK378)
Study NCT02393625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT00721110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.
Study NCT00721110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo boluses and infusions will be substituted
Study NCT00721110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
Study NCT00721110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine + Lidocaine
Description: both Ketamine and Lidocaine will be given
Study NCT00529815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
Study NCT00529815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucometer
Description: The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
Study NCT00854737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cytidine
Description: cytidine (2g po daily for 4 months)
Study NCT00854737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids
Description: omega-3 fatty acids (4g po daily for 4 months)
Study NCT00854737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill
Study NCT05116644 — intervention group
Intervention type: OTHER
Intervention: NONE - this is a cross-sectional survey design
Description: NONE - this is a cross-sectional survey design
Study NCT01586897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Metronome
Description: Providers allocated to intervention will see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
Study NCT01586897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study NCT01251757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Voice Recognition (IVR) phone calls
Description: The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and tardy calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population.
Study NCT01251757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational mailings and follow-up for nonadherence
Description: Participants received bimonthly educational materials by mail. In addition, patients received mailed refill reminder letters and their providers were notified electronically if the patients failed to refill in response to the automated calls. The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as frequently asked questions (FAQs) about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.
Study NCT03686189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iliac Bifurcation Stent Graft System
Description: Device placement after preoperative preparation. For patients with the aortoiliac aneurysm, the placement of short-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft, or the placement of long-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft are recommended.
Study NCT03539640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP: 5 cmH2O
Description: During second part of the study (MRI)
Study NCT03539640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP: 10 cmH2O
Description: During second part of the study (MRI)
Study NCT03539640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP: 15 cmH2O
Description: During second part of the study (MRI)
Study NCT04642079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20-valent pneumococcal conjugate vaccine
Study NCT03191331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Written material on healthy diet during pregnancy, dietary counseling at each maternity clinic visit given by public health nurse, group meeting with a dietician x2.
Study NCT03487458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rib Fixation Surgery
Description: Rib Fixation Surgery
Study NCT01414790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADM
Description: 29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
Study NCT03721367 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Ultrasound
Description: All individuals will undergo a blood draw for measurement of biomarkers of liver disease and an ultrasound with shear-wave elastography.
Study NCT02298946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-224
Description: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Study NCT02298946 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy(SBRT)
Description: Dose Level 1: 8Gy x 1 day. Dose Level 2: 8Gy x 3 days
Study NCT02298946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 200mg/m(2) IV on day 0.
Study NCT03975660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain Measurement Device
Description: When participants request labor analgesia, the sensors of the pain measurement device (ROPA System \[CereVu Medical, Inc. San Francisco, CA\] and Edwards Foresight device) will be applied to the forehead and connected to the device. Data recording is then started.
Study NCT04425148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: tACS is a noninvasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head.